TOOLS AND RESOURCES Sign up for updates HEAR FROM EXPERTS ABOUT THE DAMAGE THAT MAY BE CAUSED BY LARGELY UNADDRESSED INFLAMMATION AND FIBROSIS IN PATIENTS WITH CKD AND T2D1-5 The Silent Nature of CKD in T2D The Silent Nature of CKD in T2D YYMMDD Author/Uploaded by Close Increased Cardiovascular Risk in Patients with CKD and T2D Increased Cardiovascular Risk in Patients with CKD and T2D YYMMDD Author/Uploaded by Close Early Detection & Intervention in CKD and T2D Early Detection & Intervention in CKD and T2D YYMMDD Author/Uploaded by Close The Need for a Collaborative Multidisciplinary Approach in CKD in T2D The Need for a Collaborative Multidisciplinary Approach in CKD in T2D YYMMDD Author/Uploaded by Close Patient Education in CKD in T2D Patient Education in CKD in T2D YYMMDD Author/Uploaded by Close The Role of Healthcare Providers Beyond the Specialists The Role of Healthcare Providers Beyond the Specialists YYMMDD Author/Uploaded by Close Rajiv Agarwal, MD, takes us through how MR overactivation impacts inflammation and fibrosis and leads to CKD progression Rajiv Agarwal, MD, takes us through how MR overactivation impacts inflammation and fibrosis and leads to CKD progression YYMMDD Author/Uploaded by Close Peter Rossing, MD, discusses the burden that CKD presents for patients with T2D Peter Rossing, MD, discusses the burden that CKD presents for patients with T2D YYMMDD Author/Uploaded by Close Peter Rossing, MD, helps us understand the daily management needs of those living with CKD and T2D Peter Rossing, MD, helps us understand the daily management needs of those living with CKD and T2D YYMMDD Author/Uploaded by Close This video explains the mode of disease behind CKD in patients with T2D This video explains the mode of disease behind CKD in patients with T2D YYMMDD Author/Uploaded by Close Hear from patients around the world about their experiences living with CKD and T2D Hear from patients around the world about their experiences living with CKD and T2D YYMMDD Author/Uploaded by Close See how UACR acts as an early marker for CV risk and CKD progression6 Learn more CKD=chronic kidney disease; CV=cardiovascular; MR=mineralocorticoid receptor; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio. References: Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10:11552015/697010. Return to content Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Return to content Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181-191. Return to content Black LM, et al. J Histochem Cytochem. 2019;67(9):663-681. Return to content Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1-S115. Return to content Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1-150. Return to content